AVAX Technologies, Inc. Presents Results of a Dose-Response Study of MVax(R) at American Society of Clinical Oncology

PHILADELPHIA--(BUSINESS WIRE)--AVAX Technologies, Inc. (OTC Market: AVXT.OB) presented the results of its phase I-II trial of MVax®, its autologous, hapten-modified melanoma vaccine, at the annual meeting of the American Society for Clinical Oncology (ASCO) at a poster session held Sunday, June 1.

Back to news